TherapeuticsMD Inc (NYSEMKT:TXMD) a unique women’s healthcare firm reported fourth quarter and full-year fiscal report for 2016. For the year closed December 2016, net revenue was almost $19.4 million versus almost $20.1 million for the previous year. Net revenue for 4Q2016 was almost $4.5 million as against net revenue of around $5.6 million for the previous year’s quarter. This change can be attributed to a drop in the mean net sales price of their offerings, partially offset by a jump in the number of units offered.
The details
Total operating expenses for 4Q2016 and FY2016 comprised R&D expenses and SG&A. R&D expenses for FY2016 were almost $53.9 million versus around $72 million for the previous year. R&D costs for the 4Q2016 came at around $10.3 million versus close to $13.3 million in the prior year’s quarter.
The decline in R&D can be attributed to lower clinical trial expenses as the firm closed its Phase III clinical studies for TX-001HR and TX-004HR. While SG&A costs for FY2016 came at approximately $51.3 million as against about $28.7 million for the preceding year. SG&A costs for 4Q2016 were about $16.3 million as against around $8.6 million for the previous year’s quarter. The jump in SG&A were mainly due to increased sales, regulatory expenditures, marketing, and personnel costs to boost future commercialization.
Net loss for FY2016 was almost $89.9 million compared with about $85.1 million for the FY2015. While net loss in 4Q2016 was almost $22.8 million compared with about $17.5 million for 4Q2015. As of close of December 2016, cash on hand was almost $131.5 million, as against with almost $64.7 million as of close of December 2015.
In the last trading session, the stock price of jumped more than 3% to close the day at $5.84. After the recent gains, the market cap of firm stands at 1.19 billion.
